Global Bevacizumab (Biosimilar) Market Analysis by (Product, Application, Segment & Region) Global Trends, Share & Challenges Analysis & Industry Forecast (2018-2023)

June 2018 | 105 pages | ID: GFF2DC86674EN
SPER Market Research

Abstracts

REPORT DESCRIPTION

This report represents the global and regional analysis of Bevacizumab (Biosimilar) by (Product, Application, Segment & Region), market size & market growth (in terms of value & volume) trends including forecasting upto 5 years. All the region wise segmentation of buyer supplier is described properly. The report focuses on the top continent Wise (North America, Europe, Japan, China and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa) manufacturer & buyers also.

Bevacizumab (Biosimilar) Introduction

“Bevacizumab (Biosimilar)” is a cancer treatment drug known by brand name Avastin. It is a vascular endothelial growth factor directed antibody. Bevacizumab mainly targets a cancer cell protein known as vascular endothelial growth factor (VEGF). This protein helps cancers to grow blood vessels, so they can get food and oxygen from the blood. All cancers need a blood supply to be able to survive and grow. Bevacizumab blocks this protein and stops the cancer from growing blood vessels, so it is starved and can't grow. Treatments that interfere with the development of a blood supply are called anti-angiogenesis treatments.

REPORT HIGHLIGHTS

• Provide manufacturing capacity, consumption, current & past status & also the forecasting upto 2023.
• Provide complete overview including type, application & forecast region.
• Provide focused analysis of key manufacturer with their production volume, market share & also help t identify market competition landscape with SWOT analysis.
• Historical, current and projected market size in terms of volume and value.
• Analyze the global & regional potential market, advantages, risk & opportunity.
• Identify significant trends and factors driving or inhibiting the market growth.
• In-depth coverage of complete market in terms of supplier, buyer, price, trend, growth & forecasting.

The report covers application analysis on;

• Colorectal Cancer
• Lung Cancer
• Breast Cancer
• Renal Cancer
• Brain Cancer

The report covers Bevacizumab (Biosimilar) type;

• 100 mg
• 400 mg
• Other

The report covers Bevacizumab (Biosimilar) end user;

• Hospital Pharmacy
• Retail Pharmacy
• Surgical Centers
• Ambulatory Surgical Centers
• Research Institutes
• Other

The report covers exhaustive analysis on;

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies Involved
• Forecasting
• Technology

The report includes Regional analysis on;

• North America (U.S., Canada)
• Latin America (Brazil, Mexico, Rest of Latin America)
• Europe (Germany, Italy, France, U.K, Spain & Rest of Europe)
• Asia Pacific (China, India, ASEAN, Australia & New Zealand)
• Middle East and Africa (GCC Countries, South Africa, North Africa & Rest of MEA)

Top Players in Bevacizumab (Biosimilar) industry

• Genentech
• F. Hoffmann-La Roche AG
• Biocon
• Marsala Biotech
• Pfizer
• Levolta Pharmaceuticals
• Enzon Pharmaceuticals
• Hetero Drugs
• Reliance Life Science
• Beaconpharma
• Celgene Corporation
• ImClone System
• Allergan
• Acceleron Pharma
• CASI Pharmaceutical

Key Questions answered by report

• What was the market size trend of 2015-2017?
• What will be the market size trend of next 4-5 years?
• Who are the key players of Bevacizumab (Biosimilar) Raw Material?
• What are the major application industries & emerging industries?
• Who are the key vendors present in the market?
• How the future opportunities & market drivers will affect the market dynamics & ongoing trends?
• Which one segment from global coverage will be lucrative & will grow?
• What are the main market opportunities and threats faced by the vendors?
• What are the strategies are following by the existing market players?

Contents

CHAPTER 1 RESEARCH METHODOLOGY

CHAPTER 2 REPORT DESCRIPTION

CHAPTER 3 BEVACIZUMAB (BIOSIMILAR) EXECUTIVE SUMMARY

CHAPTER 4 BEVACIZUMAB (BIOSIMILAR) BASIC HIGHLIGHTS

4.1. Product Overview
4.2. CAS No & Molecular Weight
4.3. Innovator Details
4.4. Market Status

CHAPTER 5 GLOBAL BEVACIZUMAB (BIOSIMILAR) APPLICATIONS & END USER

5.1. Bevacizumab (Biosimilar) Application
  5.1.1. Colorectal Cancer
  5.1.2. Lung Cancer
  5.1.3. Breast Cancer
  5.1.4. Renal Cancer
  5.1.5. Brain Cancer
5.2. Bevacizumab (Biosimilar) Type
  5.2.1. 100 mg
  5.2.2. 400 mg
  5.2.3. Other
5.3. Bevacizumab (Biosimilar) End User
  5.3.1. Hospital Pharmacy
  5.3.2. Retail Pharmacy
  5.3.3. Surgical Centers
  5.3.4. Ambulatory Surgical Centers
  5.3.5. Research Institutes
  5.3.6. Other

CHAPTER 6 BEVACIZUMAB (BIOSIMILAR) MANUFACTURING PROCESS, RAW MATERIALS & FUNCTIONING

6.1. Bevacizumab (Biosimilar) Manufacturing Process
6.2. Bevacizumab (Biosimilar) Raw Material Involved
6.3. Bevacizumab (Biosimilar) Functioning

CHAPTER 7 BEVACIZUMAB (BIOSIMILAR) REGION WISE MARKET OVERVIEW

7.1. Bevacizumab (Biosimilar) Market Overview in Asia-Pacific (China, India, South Korea & Rest of Asia Pacific Available)
7.2. Bevacizumab (Biosimilar) Market Overview in Europe (Germany, Russia, United Kingdom & Rest of Europe Available)
7.3. Bevacizumab (Biosimilar) Market Overview in North America (Canada, US & Rest of North America Available)
7.4. Bevacizumab (Biosimilar) Market Overview in South America (Brazil, Argentina & Rest of South America Available)
7.5. Bevacizumab (Biosimilar) Market Overview in Middle East & Africa (GCC Countries, South Africa, North Africa & Rest Of MEA Available)

CHAPTER 8 BEVACIZUMAB (BIOSIMILAR) CONTINENT & COUNTRY WISE MANUFACTURERS, MANUFACTURING VOLUME & CONTACT OVERVIEW

8.1. Bevacizumab (Biosimilar) Continent Wise Manufacturers
8.2. Bevacizumab (Biosimilar) Continent Wise Manufacturing Volume
8.3. Bevacizumab (Biosimilar) Country Wise Manufacturers
8.4. Bevacizumab (Biosimilar) Country Wise Manufacturing Volume
8.5. Bevacizumab (Biosimilar) Manufacturers Contact Overview

CHAPTER 9 BEVACIZUMAB (BIOSIMILAR) GLOBAL PRICE TREND ANALYSIS OF LAST 3 YEARS

9.1. Bevacizumab (Biosimilar) Global Price Trend Analysis
9.2. Bevacizumab (Biosimilar) Country Wise Price Trend Analysis

CHAPTER 10 BEVACIZUMAB (BIOSIMILAR) INTERNATIONAL MARKET OVERVIEW

10.1. Global Demand/ Supply & Global Prices
10.2. Major Destinations Involved In Trade
10.3. Major Manufacturers (Capacities & Prices)

CHAPTER 11 BEVACIZUMAB (BIOSIMILAR) GLOBAL MARKET SIZE & MARKET GROWTH FORECASTING (2018-2023) ANALYSIS

11.1. Bevacizumab (Biosimilar) Global Market Size (Past & Future Forecasting)
11.2. Bevacizumab (Biosimilar) Global Market Growth (Past & Future Forecasting)
11.3. Bevacizumab (Biosimilar) Continent Wise Market Size (Past & Future Forecasting)
11.4. Bevacizumab (Biosimilar) Continent Wise Market Growth (Past & Future Forecasting)

CHAPTER 12 BEVACIZUMAB (BIOSIMILAR) CUSTOMER WISE CONSUMPTION, QUANTITY & CONTACT OVERVIEW

12.1. Bevacizumab (Biosimilar) Global Consumers
12.2. Bevacizumab (Biosimilar) Global Consumers As Per Consumption Quantity
12.3. Bevacizumab (Biosimilar) Continent Wise Consumer
12.4. Bevacizumab (Biosimilar) Continent Wise Consumer As Per Consumption Quantity
12.5. Bevacizumab (Biosimilar) Country Wise Consumer
12.6. Bevacizumab (Biosimilar) Country Wise Consumer As Per Consumption Quantity
12.7. Bevacizumab (Biosimilar) Consumers Contact Overview

CHAPTER 13 BEVACIZUMAB (BIOSIMILAR) CONTINENT WISE EXPORT/ IMPORT ANALYSIS

13.1. Bevacizumab (Biosimilar) Continent Wise Import Analysis
13.2. Bevacizumab (Biosimilar) Continent Wise Export Analysis
13.3. Bevacizumab (Biosimilar) Country Wise Import Analysis
13.4. Bevacizumab (Biosimilar) Country Wise Export Analysis

CHAPTER 14 BEVACIZUMAB (BIOSIMILAR) WORLDWIDE SWOT ANALYSIS

14.1. Bevacizumab (Biosimilar) Strength Analysis
14.2. Bevacizumab (Biosimilar) Weakness Analysis
14.3. Bevacizumab (Biosimilar) Opportunity Analysis
14.4. Bevacizumab (Biosimilar) Threat Analysis

CHAPTER 15 BEVACIZUMAB (BIOSIMILAR) REPORT BASED BUSINESS RECOMMENDATION